Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals Inc (NASDAQ: IONS) and Angiodynamics (NASDAQ: ANGO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals Inc (NASDAQ: IONS) and Angiodynamics (NASDAQ: ANGO).

Ionis Pharmaceuticals Inc (NASDAQ: IONS)

Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS) yesterday and set a price target of $46. The company’s shares closed yesterday at $36.38.

According to TipRanks.com, Schimmer is a 1-star analyst with an average return of -0.7% and a 44.7% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Voyager Therapeutics Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Ionis Pharmaceuticals Inc is Moderate Buy and the average price target is $39.80, representing a 9.4% upside.

In a report issued on September 28, Janney Montgomery also initiated coverage with a Buy rating on the stock with a $47 price target.
Angiodynamics (NASDAQ: ANGO)

In a report released yesterday, Jason Mills from Canaccord Genuity reiterated a Hold rating on Angiodynamics (NASDAQ: ANGO), with a price target of $17.50. The company’s shares closed yesterday at $16.47, close to its 52-week high of $17.64.

According to TipRanks.com, Mills is a 4-star analyst with an average return of 3.3% and a 57.2% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.

Angiodynamics has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.